IN2013CH04135A - - Google Patents

Info

Publication number
IN2013CH04135A
IN2013CH04135A IN4135CH2013A IN2013CH04135A IN 2013CH04135 A IN2013CH04135 A IN 2013CH04135A IN 4135CH2013 A IN4135CH2013 A IN 4135CH2013A IN 2013CH04135 A IN2013CH04135 A IN 2013CH04135A
Authority
IN
India
Prior art keywords
virus
culture
bulk
inactivated
virus bulk
Prior art date
Application number
Other languages
English (en)
Inventor
Krishna Mohan Vadrevu
Ramasamy Venkatesan
Kumar Duvuru Prasanna
Original Assignee
Bharat Biotech Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech Int Ltd filed Critical Bharat Biotech Int Ltd
Priority to AU2014338520A priority Critical patent/AU2014338520B2/en
Priority to RU2016114285A priority patent/RU2706693C2/ru
Priority to PCT/IN2014/000585 priority patent/WO2015059714A1/en
Priority to IN4135CH2013 priority patent/IN2013CH04135A/en
Priority to CN201480050520.1A priority patent/CN105744952A/zh
Publication of IN2013CH04135A publication Critical patent/IN2013CH04135A/en
Priority to PH12016500500A priority patent/PH12016500500A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN4135CH2013 2013-09-14 2014-09-08 IN2013CH04135A (https=)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2014338520A AU2014338520B2 (en) 2013-09-14 2014-09-08 A viral vaccine and methods of manufacture thereof
RU2016114285A RU2706693C2 (ru) 2013-09-14 2014-09-08 Вирусная вакцина и способы ее производства
PCT/IN2014/000585 WO2015059714A1 (en) 2013-09-14 2014-09-08 Emergency mode in a hybrid vehicle
IN4135CH2013 IN2013CH04135A (https=) 2013-09-14 2014-09-08
CN201480050520.1A CN105744952A (zh) 2013-09-14 2014-09-08 病毒疫苗及其制备方法
PH12016500500A PH12016500500A1 (en) 2013-09-14 2016-03-14 A viral vaccine and methods of manufacture thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN4135CH2013 IN2013CH04135A (https=) 2013-09-14 2014-09-08

Publications (1)

Publication Number Publication Date
IN2013CH04135A true IN2013CH04135A (https=) 2015-08-14

Family

ID=52997726

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4135CH2013 IN2013CH04135A (https=) 2013-09-14 2014-09-08

Country Status (6)

Country Link
CN (1) CN105744952A (https=)
AU (1) AU2014338520B2 (https=)
IN (1) IN2013CH04135A (https=)
PH (1) PH12016500500A1 (https=)
RU (1) RU2706693C2 (https=)
WO (1) WO2015059714A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
UA126548C2 (uk) * 2015-07-16 2022-11-02 Бхарат Біотек Інтернешнл Лімітед Вакцинна композиція для профілактики абровірусних інфекцій
WO2017083286A1 (en) 2015-11-09 2017-05-18 University Of Notre Dame Particle size purification method and devices
JP7034949B2 (ja) 2016-05-25 2022-03-14 テルモ ビーシーティー、インコーポレーテッド 細胞の増殖
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
MX2020004543A (es) 2017-11-03 2020-09-18 Takeda Vaccines Inc Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
CN116983398A (zh) 2017-11-30 2023-11-03 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物以及其使用方法
EP3581646A1 (en) * 2018-06-15 2019-12-18 Themis Bioscience GmbH Integrated manufacturing and chromatographic system for virus production
WO2020036869A1 (en) 2018-08-16 2020-02-20 Emd Millipore Corporation Closed bioprocessing device
CN111394321A (zh) * 2020-03-30 2020-07-10 无锡加莱克色谱科技有限公司 病毒颗粒纯化用超大孔径层析介质及其应用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1025209B1 (en) * 1997-08-28 2007-02-28 Cheil Jedang Corporation An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
CN102100910B (zh) * 2009-12-21 2013-01-23 北京清大天一科技有限公司 一种生产病毒疫苗的方法
WO2012073257A2 (en) * 2010-11-30 2012-06-07 Bharat Biotech International Limited Vaccine formulation for prophylaxis and treatment of chandipura virus infections in mammals
US9580692B2 (en) * 2012-02-29 2017-02-28 Ge Healthcare Bioprocess R&D Ab Method for endotoxin removal

Also Published As

Publication number Publication date
WO2015059714A8 (en) 2015-06-18
AU2014338520B2 (en) 2019-12-05
RU2016114285A3 (https=) 2018-07-16
AU2014338520A1 (en) 2016-03-31
RU2016114285A (ru) 2017-10-19
RU2706693C2 (ru) 2019-11-20
CN105744952A (zh) 2016-07-06
WO2015059714A1 (en) 2015-04-30
PH12016500500A1 (en) 2016-06-13

Similar Documents

Publication Publication Date Title
IN2013CH04135A (https=)
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
PH12018501602A1 (en) Subunit immersion vaccines for fish
EP4272746A3 (en) Crystal forms of beta-nicotinamide mononucleotide
PH12013502442A1 (en) Inactivated dengue virus vaccine
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
PH12015501526A1 (en) Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same
JO3517B1 (ar) ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
MA39819A (fr) Méthodes et compositions d'immunomodulation
HK1222205A1 (zh) 由多能干细胞产生的光感受器和光感受器袓细胞
MY192824A (en) Compound targeting il-23a and tnf-alpha and uses thereof
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX2017007196A (es) Fibroblastos de embrion de pollo inmortalizados.
EA201790847A1 (ru) Композиции и способы лечения с применением пролекарств тизоксанида, его аналога или соли
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
ZA202000574B (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
MX2020012893A (es) Formulaciones de proteinas.
EP3010340A4 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
MX2016014868A (es) Metodos para secar por congelacion y rehidratar productos biologicos.
MX2019007924A (es) Vacunas contra la influenza.
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
PL406631A1 (pl) Antygen, szczepionka przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu oraz zastosowanie antygenu określonego powyżej do wytwarzania szczepionki przeciwko grypie
WO2014188212A3 (en) Treatment and prevention of malaria
WO2014174532A3 (en) An improved process for the preparation of emtricitabine
HK40001211A (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same